Rche sur le Syst e Nerveux Central (GRSNC) (M.B., L.
Rche sur le Syst e Nerveux Central (GRSNC) (M.B., L.L., D.V., H.G.); and Centre interdisciplinaire de recherche sur le cerveau et l’apprentissage (CIRCA) (D.V., H.G.), Universitde Montr l, Montr l, Qu ec, Canada; and Centre de Recherche de l’Institut de G iatrie de Montr l, Montr l, Qu ec, Canada (H.G.).13.14.15.Sources of FundingThis study was supported by the Heart and Stroke Foundation of Canada (HSFC), Fonds de Recherche du Qu ec-Sant(FRQS), the Canada Foundation for Innovation (CFI), and the Canadian Institutes of Health Investigation (CIHR). H e Girouard was also the holder of a brand new investigator award in the FRQS along with the HSFC.16.DisclosuresNone.17.Supplementary MaterialFigures S1S18.
Circulation Reports Circ Rep 2021; three: 504 510 doi: ten.1253/circrep.CR-21-ORIGINAL ARTICLECardiovascular InterventionTORII S et al.Antiplatelet Effect of Single Antiplatelet Therapy With TXA2/TP Antagonist Storage & Stability Prasugrel and Oral Anticoagulation Immediately after Stent Implantation within a Rabbit Arteriovenous Shunt ModelSho Torii, MD, PhD; Tadashi Yamamoto, MD, PhD; Norihito Nakamura, MD; Takeshi Ijichi, MD, PhD; Ayako Yoshikawa; Yusuke Ito, PhD; Atsuhiro Sugidachi, PhD; Yuji Ikari, MD; Gaku Nakazawa, MD, PhDBackground: Antiplatelet therapy following stent implantation in individuals requiring oral anticoagulation (OAC) is controversial since triple therapy (i.e., dual antiplatelet therapy [DAPT] with OAC) is associated with a high threat of bleeding. Techniques and Benefits: In this study, 21 rabbits have been divided into five groups: prasugrel and warfarin (Prasugrel+OAC group); aspirin and warfarin (Aspirin+OAC group); prasugrel, aspirin, and warfarin group (Triple group); prasugrel and aspirin (Traditional DAPT group); and no medication (Handle group). The treated groups had been administered medication for 1 week. An arteriovenous shunt loop was established in the rabbit carotid artery for the jugular vein and 2 bare metal stents have been deployed in a silicone tube. Following 1 h of circulation, the volume of thrombi was evaluated quantitatively by measuring the amount of protein. Bleeding time was measured at the very same time. The volume with the thrombus (amount of protein) around stent struts was lowest within the Triple group, followed by the Prasugrel+OAC and Traditional DAPT groups, and was highest within the Control group. Bleeding time was the longest within the Triple group, followed by the Aspirin+OAC, Prasugrel+OAC, Conventional DAPT, and Control groups. Conclusions: This study suggests that prasugrel with OAC could possibly be a feasible antithrombotic regimen following stent implantation in individuals who need OAC therapy. Key Words: Atrial fibrillation; Dual antiplatelet therapy; Oral anticoagulant therapy; Percutaneous coronary intervention; Stent thrombosisual antiplatelet therapy (DAPT) with aspirin in addition to a P2Y12 receptor inhibitor has come to be the gold typical after percutaneous coronary intervention (PCI) to stop stent thrombosis (ST).1 With all the RIPK3 Activator site quantity of individuals with atrial fibrillation (AF) rising, it was lately reported that about ten of patients who underwent PCI had AF.two Triple therapy, consisting of DAPT plus oral anticoagulants (OAC), had been suggested to stop both ST and cardiogenic embolism. Nevertheless, recent randomized handle studies (RCTs) comparing triple therapy and dual therapy with an OAC and P2Y12 receptor inhibitor have demonstrated a significant reduction in bleeding events at the same time as similar danger of ST.3 Therefore, the newest Japanese guideline recommends triple therapy in the course of.
